Glenmark Baddi facility placed under import alert by USFDA
Glenmark said it will engage with the agency to resolve the import alert at the earliest.
New Delhi: Glenmark Pharmaceuticals has announced that the US Food and Drug Administration (USFDA) has placed the company's manufacturing plant at Baddi under import alert.
The drugs produced at the Baddi unit can now be detained without physical examination.
The USFDA inspected the facility in June 2022 and subsequently placed it under "Official Action Indicated" status. The OAI classification implied that the USFDA may withhold approval of any pending product applications or supplements filed from such facility till the outstanding observations related to non-compliance with manufacturing norms laid down by the regulator.
"We now wish to inform you that the USFDA has placed the Baddi (India) facility under import alert 66-40," Glenmark Pharmaceuticals said in a regulatory filing. As per the USFDA, import alert 66-40 implies detention without physical examination of drugs from firms which have not met drug GMPs.
"The US revenues from products supplied from this facility contributed to 1-2 percent of FY22 total revenues for the company," Glenmark said. In FY22, the company posted revenue of Rs 8,141.58 crore, as per BSE records.
Glenmark said it will engage with the agency to resolve the import alert at the earliest.
Read also: Glenmark Pharma unveils Teneligliptin plus Dapagliflozin FDC for type 2 diabetes
Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with a presence across generics, specialty and OTC businesses and with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology, and oncology.
Read also: Glenmark Specialty, Hikma Pharma launch seasonal allergic rhinitis nasal spray RYALTRIS in US
